News1
Antiviral drug remdesivir shows promise in trial on monkeys with coronavirus
probability
Publish date: Sat, 18 Apr 2020, 09:29 PM
Antiviral drug remdesivir shows promise in trial on monkeys with coronavirus
Coronavirus-infected monkeys treated with the experimental drug remdesivir improved significantly, an initial medical trial has shown. The animals showed marked improvement just 12 hours after the first treatment.
US government scientists reported Friday that the antiviral drug remdesivir has been effective in treating monkeys infected with COVID-19.
"Early treatment with the experimental antiviral drug remdesivir significantly reduced clinical disease and damage to the lungs of rhesus macaques infected with SARS-CoV-2, the coronavirus that causes COVID-19," said a press release from the National Institutes of Health, which ran the experiment.
The small study, which is preliminary and has yet to be peer-reviewed, mimicked treatment procedures that are being used in a large human trial conducted on patients who have been hospitalized with either the COVID-19 disease or the SARS-CoV-2 virus.
Remdesivir works against the COVID-19 by adding mutations that ultimately destroy the virus.
Read more: Japan pushes Avigan drug against COVID-19
Improvement after first treatment
In the experiment with monkeys, two groups of six rhesus macaques were intentionally infected with the respiratory virus. The test group was treated with the drug, developed by Gilead Sciences, while the untreated comparison group was not.
Some patients are receiving treatment with remdesivir in trials
The test group was given its first dose of the drug intravenously 12 hours after the initial infection, then every day for the next six days. The first treatment was timed to occur just before the virus reached its maximum level in the monkeys' lungs.
Twelve hours after the first treatment, the macaques' symptoms had significantly improved. Their conditions continued improving over the week.
At the end of the test phase, just one of the six treated animals displayed mild difficulty breathing, while all six animals in the untreated group had difficulty breathing.
The treated group also displayed significantly lower levels of the virus in their lungs than the untreated group and also had less lung damage.
Read more: Could an existing drug help against the new coronavirus?
More trials underway
Remdesivir is one of the first drugs thought to be capable of treating the new coronavirus. Clinical trials are already underway with human patients.
On Thursday, it was reported that the drug had also been regarded as effective on coronavirus patients in Chicago who are participating in the trial.
More articles on News1
How hedging for refining margin causes derivative loss / gain: HENGYUAN
Created by probability | Jun 02, 2022
ASIAN COMPANIES to ramp up petrol exports to US as sky-high prices beckon - HENGYUAN
Created by probability | May 21, 2022
Discussions
Be the first to like this. Showing 17 of 17 comments
probability........1% fatality rate, 80% mild cases....any placebo also can be called a Cure...just have to have right attitude.
there is no known drug for any disease giving better results..........
imagine a cancer drug giving u 1 % fatality rate, 80% mild cases, u will take it.
2020-04-18 21:40
furthermore almost all the fatal cases in malaysia had prior existing health problems
2020-04-18 21:43
remember HIV came from ape to humans...and ape shares 96% identical genes with humans
almost like the difference between men and women..lol!
2020-04-18 21:44
Going to hear plenty of Covid19 killer in days ahead just like those Tesla killer thingy! In the end, only hot air! Keeping expectation very low!
2020-04-18 21:45
what will likely happen is that remdesivir will be combined with some physical aid like intense oxygen ventilator to reduce the fatality rate zero..
2 or 3 magic bullets combined will kill the virus
2020-04-18 21:52
https://www.nih.gov/news-events/news-releases/antiviral-remdesivir-prevents-disease-progression-monkeys-covid-19
Antiviral remdesivir prevents disease progression in monkeys with COVID-19
Study supports clinical testing under way across U.S.
What
Early treatment with the experimental antiviral drug remdesivir significantly reduced clinical disease and damage to the lungs of rhesus macaques infected with SARS-CoV-2, the coronavirus that causes COVID-19, according to National Institutes of Health scientists.
The study was designed to follow dosing and treatment procedures used for hospitalized COVID-19 patients being administered remdesivir in a large, multi-center, clinical trial led by NIH’s National Institute of Allergy and Infectious Diseases (NIAID). The scientists posted the work(link is external) on the preprint server bioRxiv. The findings are not yet peer-reviewed and should not be considered clinical advice, but are being shared to assist the public health response to COVID-19. A study detailing the development of the rhesus macaque model of mild- to-moderate human disease, conducted by the same team of NIAID scientists, was posted to bioRxiv(link is external) on March 21.
The current study of remdesivir, a drug developed by Gilead Sciences Inc. and NIAID-supported investigators, involved two groups of six rhesus macaques. One group of monkeys received remdesivir and the other animals served as an untreated comparison group. Scientists infected both groups with SARS-CoV-2. Twelve hours later the treatment group received a dose of remdesivir intravenously, and then received a daily intravenous booster dose thereafter for the next six days. The scientists timed the initial treatment to occur shortly before the virus reached its highest level in the animals’ lungs.
Twelve hours after the initial treatment, the scientists examined all animals and found the six treated animals in significantly better health than the untreated group, a trend that continued during the seven-day study. They report that one of the six treated animals showed mild breathing difficulty, whereas all six of the untreated animals showed rapid and difficult breathing. The amount of virus found in the lungs was significantly lower in the treatment group compared to the untreated group, and SARS-CoV-2 caused less damage to the lungs in treated animals than in untreated animals.
The investigators note that the data supports initiating remdesivir treatment in COVID-19 patients as early as possible to achieve maximum treatment effect. The authors, from NIAID’s Rocky Mountain Laboratories in Hamilton, Montana, also note that while remdesivir helped prevent pneumonia, it did not reduce virus shedding by the animals. “This finding is of great significance for patient management, where a clinical improvement should not be interpreted as a lack of infectiousness,” they write.
2020-04-18 21:59
Basically what they are saying is, Remdesivir if used early upon infection, it completely halts progression to critical stage/point of no return
If used early, its completely effective
.......................................
2020-04-18 22:03
These are therapeutic - that is to cure once you had the disease. Traditional Chinese Medicine is also known to be therapeutic.
Vaccine on the other hand prevent (stop) one that is vaccinated from getting the disease.
2020-04-19 12:10
this article is old
drug already out
Gilead Remdesivir cures in 5 days
US has it
problem now is the production and distribution
so covid-19 still with us for the next 6 months to 1 year
it only means that covid-19 wun kill so many any more until the next mutation.
who has it? no one has it.... so people will continue dying.
but of course it means monday BURSA will be green and limit up
DOW already extreme green on friday after this news leaked out in advance.
2020-04-19 12:17
Actually, the cheapest option on the table is to curb Covid19! I think Malaysia is on the way to do it! We succeed! However, sad to say, our neighbours and the western nations refuse to accept a simple common sense! Just look at USA, from few hundred grew into half a million in few months only, why, because they refuse to be quarantine, the infected refuse to be segragrated from healthy ones! This is all because of 'it's my human rights' mentality!
2020-04-19 12:19
financial markets works on opinions.... if people think it works.... it works
2020-04-19 12:30
Post a Comment
Featured Posts
Apps
Top Articles
1
2
3
4
Good Articles to Share
5
6
7
Good Articles to Share
Slower US Fed pivot weakens rate-cut bets across emerging Asia
8
Good Articles to Share
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
MQ Trading Signals
Stock
Time
Signal
Duration
Stock
Time
Signal
Duration
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
probability
while the media keep talking about vaccines 18 months away....DJIA keep going up..recovered from 18,000 to 24,300 and now we have news suddenly saying experimental drugs curing people with Covid 19
2020-04-18 21:32